WO2007029107A1 - Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r - Google Patents

Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r Download PDF

Info

Publication number
WO2007029107A1
WO2007029107A1 PCT/IB2006/002474 IB2006002474W WO2007029107A1 WO 2007029107 A1 WO2007029107 A1 WO 2007029107A1 IB 2006002474 W IB2006002474 W IB 2006002474W WO 2007029107 A1 WO2007029107 A1 WO 2007029107A1
Authority
WO
WIPO (PCT)
Prior art keywords
designates
ome
compound according
compound
alkyl
Prior art date
Application number
PCT/IB2006/002474
Other languages
English (en)
Inventor
Jan Gunzinger
Kurt Leander
Original Assignee
Analytecon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Analytecon Sa filed Critical Analytecon Sa
Priority to US11/991,531 priority Critical patent/US20090099133A1/en
Priority to BRPI0616731A priority patent/BRPI0616731A2/pt
Priority to AU2006288847A priority patent/AU2006288847A1/en
Priority to EA200800786A priority patent/EA200800786A1/ru
Priority to EP06795449A priority patent/EP1940796A1/fr
Priority to JP2008529711A priority patent/JP2009507820A/ja
Priority to CA002621820A priority patent/CA2621820A1/fr
Publication of WO2007029107A1 publication Critical patent/WO2007029107A1/fr
Priority to NO20081206A priority patent/NO20081206L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems

Definitions

  • the present invention relates to novel compounds and prodrug compounds capable of down-regulating or inhibiting the expression or function of the insulin-like growth factor- 1 receptor (IGF-IR) .
  • the invention is also directed to pharmaceutical compositions and methods of down-regulating or inhibiting IGF-IR expression or function in order to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of this receptor is observed.
  • IGF-IR insulin-like growth factor- 1 receptor
  • the present invention is an improvement of some aspects over PCT/CH2004/000147 from the same applicant, the content of which is incorporated heroin by reference in its entirety .
  • the insulin-like growth factor receptor is one of 58 trans-membrane tyrosine kinase receptors present in humans [Review: Structure and function of the Type 1 insulin- like growth factor receptor. T.E.Adams et al. Cell. MoI. Life Sci. 57 (2000) 1050-1093; Jnsulin-Like Growth Factors. Kluwer Academic/Plenum Publishers (2003). Editors: LeRoith, D., Zumkeller, W. and Baxter, R.C.]. Genetic evidence and studies on cells lacking the IGF-I receptor have demonstrated that it is required for optimal growth, but not an absolute condition for growth [Baserga et al. Biochim. Biophys.
  • antisense oligonucleotides to inhibit the IGF-I receptor expression in keratinocytes has been shown Lo reverse the epidermal hyper proliferation in psoriasis lesions [CJ. Wraight et al. Nat. Biotechnol. 18(2000) 521- 526] .
  • Down-regulation of the IGF-I receptor would possibly a ] so have beneficial effect with respect to diseases such as diabetic retinopathy [L. K. Shawver Gt al. DDT 2(1997) 50-63] as well as atherosclerosis, restinosis [A. Bayes-Genis et al. Circ. Res. 86(2000) 125-130] and rheumatoid arthritis [J.Pritchard et al . J. Immunol. 173(2004) 3564-3569].
  • diseases such as diabetic retinopathy [L. K. Shawver Gt al. DDT 2(1997) 50-63] as well as atherosclerosis, restinosis [A. Bayes-Genis et al. Circ. Res. 86(2000) 125-130] and rheumatoid arthritis [J.Pritchard et al . J. Immunol. 173(2004) 3564-3569].
  • the IGF-I receptor system is regarded as an attractive target in the prevention and/or treatment of diseases that are dependant on an expression or over-expression of the IGF- 1 receptor for their proliferation [L. Long et al. Cancer Research 55(1995) 1006-1009, R. Baserga TIBTECH 14 (1996) 350- 152; R. Baserga et al. Endocrine 7 (March 1997) 99-102; V. M. Macaulay et al. Annals of Oncogene 20(2001) 4029-4040; A.J.Salisbury et al. Horm. Metab. Res. 35(2003) 843-849; Mitsiades, CS. et al. Cancer Cell 5(2004) 221-230].
  • tyrphostins A series of substances, named tyrphostins, have been claimed to down-regulate or inhibit the expression of the IGF-I receptor [M. Parrizas et al. Endocrinology 138 (1997) 1427-1433; G. Blum et al. Biochemistry 39(2000) 15705-15712; G. Blum et al. J. Biol. Chem. 2/8 (2003) 40442-40454].
  • the drawback with the tyrphostins are their low acLivity in cell systems and that they cross-react with the insulin receptor.
  • tamoxifen at high concentration, has the ability to down-regulate or inhibit the tyrosine phosphorylation of the IGF-IR ⁇ -subunit, thereby blocking downstream signalling.
  • PCT/CH2004/000147 (Analytecon S. ⁇ .) provides new heterocyclic compounds with surprisingly improved LGF-IR down-regulating activity.
  • the present invention aims at providing new compounds with high IGF-IR down-regulating activity, wherein the above- identified problems are successfully solved.
  • the invention also aims at providing a pharmaceutical prodrug composition, wherein water solubility, stability and the like of the active parent compounds described herein and in PCT/CH2004/000147 are improved.
  • R 4 designates H; OH; CN; trifluoromethyl; NH 2 ; NHCN; NHCOCH 3 ; NHCOCH ? CH 3 ; NHCHO; NHCOOCH 3 ; amino (Ci-C 6 ) alkyl; amino (Ci-C 3 ) dialkyl; (C x -Ce) alkoxy; (Ci-C 6 ) alkyl; carbonyl-R 9 wherein R 9 designates hydrogen, (Ci-C 6 ) alkyl , (Ci- Cg) alkoxy; (Ci-C 6 ) alkyl -R 10 ; (Ci-C 6 ) alkoxy-Ri 0 ; amino (C x -C 6 ) alkyl - Rio and amino (Ci-C 3 ) dialkyl-Ri 0 whereby Ri 0 designates at least one OMe, OEt, OPr, OIsopropyl, OH, CN, NH 2
  • R 2 designates hydrogen, Me, Et, CHO, CN, OH, OMe, COR 9 , COOR 9 , CONHR 9 or CSNHR 3 , whereby R 9 denotes (C 1 -C 4 ) alkyl ;
  • R 5 designates hydrogen, (Ci-C 4 ) alkyl, OH, (C 1 - C 4 ) alkoxy, (Ci-C 2 ) alkoxy partly or fully fluorinated, trifluoromethyl , halogen or OX;
  • R 6 designates Me, halogen, hydrogen, (C 1 -C 4 ) alkoxy, (Ci- C 2 ) alkoxy partly or fully fluorinated, SMe or SEt; if R 3 is OH or OX, R 6 may be hydrogen; n is 1 or 2;
  • R 3 1 and R 5 ' each independently designate OH, Me, Et, OMe, OMe partly or fully fluorinated, trifluoromethyl or halogen;
  • U designates N or CR 2 1 , whereby R 2 1 denotes hydrogen, (Ci-C 4 ) alkyl, (Ci-C 4 ) alkoxy, trifluoromethyl or halogen;
  • V designates N or CR 4 1 , whereby R 4 1 denotes hydrogen, (Ci-C 6 ) alkoxy, (Ci-C 4 ) alkoxy partly or fully fluorinated, (Ci- C 6 ) alkyl, OH, trifluoromethyl, halogen or OX;
  • W designates N or CR 6 1 , whereby R 6 1 denotes hydrogen, (Ci-C 4 ) alkyl, (C 1 -C 4 JaIkOXy, trifluoromethyl or halogen,-
  • OX designates a group capable of conferring a prodrug property; and pharmaceutically acceptable salts thereof, where applicable (see below) .
  • prodrug compounds having the following general formula (II) :
  • OX groups may be present in both R 5 and R 4 ' (when V designates CR 4 ') .
  • Preferred embodiments of the prodrug compounds (II) are derivable from the following description.
  • Figure 1 shows the rate of dephosphorylation of (IR)- 1- (3, 4 , 5-trimethoxyphenyl) -2-formyl-5- (dihydrogen phosphate) - 6-methoxy-l, 2, 3, 4-tetrahydroisoquinoline by alkaline phosphatase.
  • a “prodrug” is an entity which either comprises an inactive form of an active drug (parent compound) or includes a chemical group which confers preferred characteristics on the drug.
  • the invention concerns a composition which has the potential of producing a desired physiological effect on cells, but is initially inert (i.e. does not produce said effect) , and only after undergoing some modifications becomes physiologically active and produces said physiological effect on cells.
  • the derivative of a parent compound of the present invention has a chemically or metabolically degradable group, and becomes pharmaceutically active after biotransformation.
  • Biotransformation of the prodrug or a salt thereof, according to the invention is carried out under physiological conditions (in vivo) and is a result of a reaction with an enzyme, or a body fluid such as gastric acid, blood etc., thus undergoing an enzymatic oxidation, reduction, hydrolysis etc. or a chemicaJ hydrolysis to convert into the active parent compound.
  • an enzyme or a body fluid such as gastric acid, blood etc.
  • a body fluid such as gastric acid, blood etc.
  • physiological effect concerns any effect a drug may have on eel Ls, in order to improve the health of the subject administered with the drug.
  • the effect is produced in order to treat, prevent a disease, a defect or pathological condition or to alleviate some of the manifestations of a disease, defect or pathological condition.
  • Tn the above formula (T) preferably Ri is H, OH, NHz, a ⁇ no (Ci-C 3 ) , ami no (Ci-C 3 ) dialkyl, CH 2 OH, COOCIl 5 , OCOOCH 3 , methyl, Et and the J i ke .
  • R 2 is Me, OH, CN, CHO, COR 9 or COOR 9 ; particuJ arly preferred examples of R 2 are Me (methyl), CHO (formyl), COMe (acetyl) and CN (cyano) .
  • R 5 is hydrogen, OH, Mc, OMe, halogen or OX; and preferably R 6 is OCHF ? , OMe, OCH 2 -CF 3 or OEt. Particularly preferably R 5 is hydrogen, OX, OH or OMe and R 6 is OCHF?, OMe OCH 7 CF 3 Or OEt.
  • R 3 1 , R 5 ' each independently chloro, bromo, Me, OMc or OCHF 2 .
  • R 3 1 and R 5 ' are identical. Jn another preferred embodiment they are both chloro, both bromo, both Me, both OMe, or both OCHF 2 ; in another preferred embodiment R 3 ' is chloro or bromo, and R 5 ' is OMe. Most preferably both R 3 ' and R 5 ' are chloro, bromo or OCHF ? .
  • R 2 ' and R 6 ' are preferably hydrogen.
  • R 4 ' then is preferably hydrogen, OH, chloro, bromo, Me, OMe, OCHF ? or OX.
  • the alkyl residue in the (Ci-C 4 ) alkyl or (Ci-C 4 ) alkoxy, as used in the substituent definitions of formula (I)/ may be branched, unbranched or cyclic and may contain double or triple bonds. It is e.g. methyl / ethyl, n-propyl, n-butyl, iso- propyl, sec-butyl, t-butyl, cyclopropyl, cyclobutyl, ethenyl, prop-2-enyl or prop-3-enyl, but-1-enyl, but-2-enyl, but-3- enyl or propargyl . Preferably it is methyl, ethyl or isopro- pyl; particularly preferably it is methyl.
  • the alkyl residue in the (Ci-C 6 ) alkyl or (Ci-C 6 ) alkoxy may be unbranched, branched or cyclic and may contain double or triple bonds.
  • unbranched alkyls are methyl, ethyl, n-propyl, n-butyl, n-pentyJ and n-hexyl.
  • branched alkyl examples include isopropyl, sec-butyl, t-butyl, (1,1-di- ethyl)methyl, (1-propyl-l-methyl) methyl, (1-isopropyl-l- methyl) methyl, (1, 1 -dimethyl-l-ethyl)methyl, (1-t-bu- tyl)methyl, (1-propyl-l-cthyl) methyl, (1-isopropyl-l- ethyl) methyl, (1, 1-diethy] -] -methyl) methyl and (1-L-butyl-l- methyl) methyl .
  • Examples of the cyclic aJ kyl are cycLopropyl, cyclobutyl, cyclopentyl, cyclohexyi or (2- or 3- methyl) cyclopentyl .
  • Examples of unsaturated alkyls are ethenyl, prop-2-eny3 , but-1-enyl, but-2-enyl, but-3-enyl, pent-1-enyl, pent-2-enyl, pent-3-enyi, pent-4-enyl, penta- 1,3-dienyl, penta-1, 4-dienyl, penta-2, 4-dienyl or propargyl .
  • halogen means xr ⁇ the context of the present application fluoro, chloro or bromo.
  • TGF- 1 receptor encompasses human IGF-I receptor, tho amino acid sequence of which is known [see e.g. T. E. Adams et al. Cellular and Molecular Life Sciences 2000, 57, p. 1050-1093], but it also encompasses other IGF-IR, such as IGF-IR of mammals in general.
  • the prodrug compounds of formula (II) comprise one OX group in either R 5 or Rj', or OX groups may be present in both R 5 and R 4 1 (when V designates CR 4 1 ) .
  • -OX groups designate phosphate derivatives, ester derivatives, carbonate derivatives (acyloxy derivatives of the parent compounds) and/or linked poly (ethylene glycol) derivatives as described below. Any other suitable derivatives known by those skilled in the art and considered as equivalents may also be used in the scope of the present invention.
  • a carbonate derivative prepared by reacting the parent compounds with a suitable alkyl- or arylchloroformate, are exemplified as prodrugs.
  • Particularly preferred derivatives as prodrugs are -OCOOCH3 - OCOOC 2 H 5 , -OCOOPropyl, -OCOOIsopropyl, -OCOOBu, -OCOO (m-
  • ester derivatives are formates, acetates, benzoates (e.g. OCO(m-COONa-Ph) , dimethylglycine esters, aminoalkyl esters, carboxyalkyl esters, esters with amino acids and the like.
  • the invention also encompasses chemical modifications of the parent compounds to prolong their circuJating lifetimes.
  • suitable poly (ethylene glycol) derivatives that possess this property are described in e.g. US 2005171328 (NEKTAR THERAPEUTICS AL CORP) or US 6,713,454 (NOBEX CORP) . Since the parent compounds are lipophilic, the PEG-oligomer/polymer also increases the hydrophilicity of the prodrugs and thereby their aqueous solubility.
  • OX groups designate phosphate derivatives.
  • Prodrug compounds of particular interest are (IR) -3 - (3, 4, 5-trimethoxyphenyl) -2-formyi- 5- (dihydrogen phosphate) -6-methoxy-l, 2,3, 4-tetrahydro- isoquinoline, (IR) -1- (3, b-dichlorophenyl) -2-formyl-5- (dihydrogen phosphate) -6-difluoromethoxy-1, 2,3,4- totrahydroisoquj noline and (IR) -1- [3, 5-dichloro--4- (dihydrogen phosphate) phenyl] -2-irormyl-6-difluoromethoxy-1, 2,3,4- tetrahydroisoquinoline and their corresponding 6- (2, 2, 2-tri- fluoroethoxy) , ?-cyano and 2-acetyl derivatives, and salts thereof .
  • the above substances may be synthesized from their parent compounds, which contain a 5- or a 4 '-hydroxy group, by reaction with phosphoroxychloride, followed by hydrolysis to the corresponding phosphate [see e.g. US 5,637,680 (Etoposide phosphate) ] .
  • Other suitable reagents are dibenzyl phosphite in combination with carbon tetrachloride (Example 1) and diethyl chiorophosphate (Examples A and 6) .
  • pharmaceutically acceptable salts are produced from acidic inorganic or organic compounds, ox alkaline inorganic or organic compounds .
  • pharmaceutically acceptable salt refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise s undesirable.
  • the pharmaceutically acceptable salts of the compounds of formula (I) and/or the prodrug compounds of formula (II) are acid addition salts with pharmaceutically acceptable acids, which are possible in the case where R2 is hydrogen, Me or Et; and/or at least one of U, V and W is ni- 0 trogen, and when the group OX contains a basic nitrogen atom.
  • a desired salt may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid, and the 5 like, or with an organic acid, such as formic acid, acetic acid, maleic acid, succinic acid, mandelic acid, maleic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid; a pyranosidyl acid, such as glucuronic acid or galacturonic acid; an alpha-hydroxy acid, 0 such as citric acid or tartaric acid; an amino acid, such as aspartic acid or glutamic acid; an aromatic acid, such as benzoic acid or cirmamic acid; a sulfonic acid, such as methanesulfonic acid, p-toluenesulfonic acid or ethanesulfonic acid;
  • the preferred ammonium salts are derived from hydrochloric, hydrobromic, methanesulfonic, acetic, propionic, benzoic, citric, tartaric, malic, maleic, fumaric, lactic, nitric, and phosphoric or succinic acid.
  • the salts are prepared by reacting the free base with stoichiometric amounts or with an excess of the desired salt forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
  • the free base can be dissolved in a mixed aqueous solution of the appropriate acid and the salt recovered by standard techniques, for example, by evaporation of the solution.
  • the free base can be charged into an organic solvent such as a lower alkanol, symmetrical or asymmetrical ethers containing 2 to 10 carbon atoms, an aLkyl ester, or mixtures thereof, and the like, and then it is treated with the appropriate acid to form the corresponding salt.
  • the salt is recovered by standard recovery techniques, for example, by filtration of the desired salt from the mixture, or it can be precipitated by the addition of a solvent in which the salt is insoluble and recovered Lhere from.
  • suitable inorganic and organic solvents for performing the various reactions include any inorganic or organic solvent that does not adversely affect the reactants or the resulting product, including halogenated solvents such as methylene chloride, chloroform, ether solvents such as diethyl ether, and other so] vents such as tetrahydrofuran, dioxane, diglyme, cyciooctane, benzene or toluene, heptane, cyclohexane, aliphatic as well as cycloaliphatic and aromatic hydrocarbon solvents, water, acidified aqueous solutions, mixed organic and inorganic solutions, ethyl acetate, propyl acetate and mixtures thereof.
  • halogenated solvents such as methylene chloride, chloroform, ether solvents such as diethyl ether, and other so] vents such as tetrahydrofuran, dioxane, diglyme, cyc
  • salts formed from acidic prodrugs such as phosphates, and alkaline inorganic or organic compounds.
  • Preferred inorganic cations comprised in the salts are lithium, sodium, potassium, rubidium, ammonium, calcium, magnesium, zinc and manganese. Production of phosphate salts are described in e.g. G. R. Pettit et al. Anti-Cancer Drug Design 16 (2001) 185-193.
  • Preferred salts also include those formed from acidic prodrugs and organic amines, including, but not limited to, imidazole and morpholine. Alkaline amino acid salts may also be used.
  • amino acids designates, according to the invention, in particular the [alpha] -amino acids occurring in nature, but moreover also incLudes their homologues, isomers and derivatives. Enantiomers can be mentioned as an example of isomers. Derivatives can be, for example, amino acids provided with protective groups.
  • Preferred alkaline amino acid are arginine, ornithine, diaminobutyric acid, lysine or hydroxy lysine and especially L-arginine, L-lysine or L- hydroxy lysine; an alkaline dipeptide or a pharmaceutically acceptable alkaline amino acid derivate.
  • one starting material is a phenethylamine substituted in the aromatic part.
  • the starting material is a phenethylamine that in addition may have a substituent on the benzylic carbon atom.
  • Some of these starting materials are available by alkylation of a suitable substituted phenylacetonitril, followed by reduction to the amine [Organic Syntheses, Coll. Vol. 76, p. 169; S ⁇ kata, K. Bull. Chem. Soc. Jpn . 56 (1983) 3306-3307], or via substituted ⁇ -nitrostyrenes [Ambros, R. et al. J. Med. Chem. 33 (1990) 153-160; Schafer, H. et al. Tetrahedron 51 (1995) 2305-2334].
  • Suitable protecting groups for aromatic hydroxyl groups in the present invention are e.g. benzyl and i sopropyl groups. Removal of the benzy] group and the isopropyl group is easily achieved by catalytic hydrogenation (catalyst Pd/carbon) and treatment with BCI 3 , respectively.
  • Another usefu.1 reagent is trimethyliodosilane, which selectively removes isopropyl groups in the presence of difluoromethoxy groups .
  • the parent compounds of prodrugs (31) resulting from the biotransformation of the prodrug compounds according to the invention can be prepared using the methods described in the following Examples 1, 4, 5 and 6 as well as in PCT/CH2004/000147, the content of which is incorporated herein by reference in its entirety.
  • Some preferred compounds (I) contain one or several difluoromethoxy groups.
  • An intermediate in the synthesis of some compounds (I) is 2-(3- difluoromethoxyphenyl) ethylamine, which is synthesized from 3-difluoromethoxybenza Ldehyde (commercially available) according to the general procedures described in PCT/CH2004/000147.
  • Another useful starting material is 2- benzylox ⁇ -3-difluoromethoxybenzaldehyde, which is available by difluoromethylation [in analogy with Guay, D. et al. Med. Chem. Lett. 12 (2002) 1457-1461] of 2-benzyloxy-3-hydroxy- benzaldehyde [Kessar, S. V. et al. J.Org, Chem. 53 (1988) 1/08-1713].
  • Other starting materials can be produced from suitable hydroxylated benzoic acids.
  • the compounds and the prodrug compounds of the present invention contain at least one chiral centre and therefore may exist in different enantiomeric forms.
  • particularly preferred compounds (I) and prodrug compounds (II) are enanti omerical Iy pure the scope of the present invention is intended to cover both enantiomers per se, as we.1.1 as mixtures of them in any ratio, such as racemic mixtures .
  • Prodrug compounds (II) of the present invention may be obtained in their enantiomerically pure forms by using enantiomerically pure parent compounds as starting material.
  • Enantiomerically pure compounds (I) and prodrug compounds (II) may also be obtained from their racemates by crystallization of their addition salts with chiral acids [see e.g. D. L.
  • the compounds (I) and/or prodrug compounds of formula (II) and their pharmaceutically acceptable salts, where applicable, may be administered in the form of a pharmaceutical composition in which they are in association with a pharmaceutically acceptable adjuvant, diluent or car- rier, in order to prevent or treat any disease in which inhibition of the IGF-I receptor would be considered beneficial by the skilled person.
  • the present invention also provides a pharmaceutical composition comprising the prodrug compounds of formula (I), or a pharmaceutically acceptable salt thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • diluents and adjuvant reference may be made to the standard literature describing these, e.g.
  • the compounds (T) and/or prodrug compounds of formula (II) may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsi ons .
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • macroemulsi ons Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol , A. Ed. (1980) .
  • Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi permeable matrices of solid hydrophobic polymers containing the prodrug compounds (1), which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethy L-methacrylate) , or poly (vinylalcohol) ) , polylactides (U.S. Pat. No.
  • compositions of the invention will preferably comprise from 0.001 to 50 % by weight of compound (D •
  • the prodrug compounds (II) once transformed by the organism into their corresponding active parent compounds have IC 50 activities in intact cell systems ranging from 8 microgram/ml to 150 picogram/ml . Due to the large difference in activities, the pharmaceutical compositions of the invention will preferably comprise from 0.001 to 50 % by weight of prodrug compounds (II).
  • the daily dose of the compounds (I) and/or prodrug compounds of formula (II) will necessarily be varied depending upon the host treated, the particular route of administration, and the severity and kind of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient .
  • compositions of the invention may be formulated as creams, gels, solutions, ointments, suspensions or plasters etc. when intended for topical administration; for administration by inhalation, e.g. as aerosols or dry powders; for oral administration, e.g. in the form of tablets, capsules, gels, syrups, suspensions, solutions, powders or granules; for rectal or vaginal administration e.g. as suppositories; or for parenteral injection (including in- travenous, subcutaneous, intramuscular, intravascular, or infusion) as a sterile solution, suspension or emulsion.
  • parenteral injection including in- travenous, subcutaneous, intramuscular, intravascular, or infusion
  • the compounds (I) and/or the prodrug compounds (II) of the present invention once transformed by the organism into corresponding active parent compounds were found to down- regulate or inhibit the expression or function of the human IGF-l receptor, without inhibiting the structurally closely related insulin receptor. They were found to promote apop- tosis of malignant cells and to interfere with cell division by blocking the cells in the prophase of the mitotic cycle.
  • the resulting active parent compounds are useful for the prevention and/or treatment of diseases of unregulated TGF-IR expression, including eel] proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases e.g. psoriasis, autoimmune diseases e.g. rheumatoid arthritis, and transplant rejection.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. Hence, the mammal to be treated herein may have been diagnosed as having the disorder or may be predisposed or susceptible to the disorder.
  • “Mamma]/' for purposes of treatment refers to any animal classified as a mammal, including, but not limited to, humans, domestic and farm animals or pet animals, such as dogs, horses, cats, cows, monkeys etc. Preferably, the mammal is human.
  • the term "therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal.
  • the therapeutically effective amount of the drug may reduce the number of cancer s cells; reduce the tumour size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumour metastasis; inhibit, to some extent, tumour growth; and/or relieve to some extent one or more of io the symptoms associated with the cancer.
  • the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
  • terapéuticaally effective amount is used herein to mean an amount sufficient to prevent, or preferably reduce by at i5 least about 30 percent, preferably by at least 50 percent, preferably by at least 70 percent, preferably by at least 80 percent, preferably by at least 90%, a clinically significant change in the growth or progression or mitotic activity of a target cellular mass, group of cancer cells or tumour, or
  • cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • the compounds (I) and/or prodrug compounds of formula (II) may bo used against cell proliferate diseases in combination with conventional treatments such as irradiation and/or one or more chemotherapeutic agents such as e.g.
  • a chemotherapoutic agent When a chemotherapoutic agent is used in combination with the compounds (I) and/or prodrug compounds of formula [LL), then this may be used in the form of a medicament containing a combination of these two agents, for simultaneous administration, or they may be used in the form of separate dosage forms, each containing one of the agents, and in the latter case the individual dosage forms may be used e.g. sequentially, i.e. one dosage form with the compounds (I) and/or prodrug compounds of formula (TT) 7 followed by a dosage form containing the chemotherapeutic agent (or vice versa) .
  • This embodiment of two separate dosage forms may be conceived and provided in the form of a kit.
  • the Kit comprises a container and a Label or package insert on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a prodrug composition or the transformed active parent composition that is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
  • the label or package insert indicates that the composition is used for treating the condition of choice, such as cancer.
  • the compounds (1) and/or prodrug compounds of formula (II) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardization of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • step 3 The imine (47.0 g) produced according to step 2 was dissolved in a mixture o£ methanol (250 ml) and 1,2- dimethoxyothdne (250 ml) and treated with sodium borohydride at 10°C until no starling material remained (TLC: silica ge3 /ethyl acetate). The mixture was concentrated to dryness and partitioned between aqueous sodium hydroxide (400 ml, 2M) and dichl oromethane (400 ml). The organic phase was separated, dried and concentrated to dryness, leaving the secondary amine (46.4 g) . An analytical sample was obtained by crystallization from ethanol, giving a white solid, m.p. 122- 124°C.
  • the acetyl-D-leucine salt (29.5 g) produced according to step 1 above was partitioned between dichloromethane (300 ml) and aqueous sodium hydroxide (200 ml, 2M) .
  • the organic phase was dried and concentrated to dryness leaving the secondary amine.
  • a solution of the amine, toluene (400 ml) and formic acid (20 ml) was refluxed for 18 hours using a Dean-Stark trap.
  • the reaction mixture was concentrated to dryness, leaving the formyl derivative of the 5-benzylether as a viscous oil.
  • Example 2 Solubiliby of ( 1R) -1- (3,4, 5-trimethoxy- phenyl ) -2- Eormy] -5- (dihydrogen phosphate) -6-methoxy-l, 2, 3, 4- tetrahydroisoquinoline in a physiologically acceptable buffer
  • bovine alkaline phosphatase type VII S, Sigma-Aldrich
  • titJe compound The ability of bovine alkaline phosphatase (type VII S, Sigma-Aldrich) to dephosphorylate the titJe compound was investigated in vitro. It was found that the half-Life time is 8.0 minutes at a phosphatase concentration of 10 units/ml (37 0 C, pH 7.4). Intravenous administration of the titie compound is consequently expected to result in a rapid formation of the active moiety (IR) -1- (3, 4, 5-trimethoxy- phenyl) -2-formyl-5-hydroxy- ⁇ -methoxy-l, 2, 3, 4-tetrahydroiso- quinoline (see Figure 1).
  • IR active moiety
  • Triraethylbromosilane (9.2 g) was added to a solution of (IR) -]- (3, 5-dichlorophenyl) ⁇ 2-acetyl-5- (diethyl phosphate) -6-ethoxy-l, 2, 3, 4-tetrahydroisoquinoline (7.5 g) in dichloromethane (50 ml) . After stirring at room temperature for 17 hours, dichloromethane and (150 ml) and water (200 ml) were added. The organic phase was separated, dried and o concentrated to dryness, leaving a white solid (6.2 g) .
  • step 4 The imine (0.8 g) produced according to step 4 was dissolved m methanol and (100 ml) treated with sodium borohydride at room temperature until no starting material remained (TLC: silica gel/ethyl acetate) . The mixture was concentrated to dryness and partitioned between aqueous sodium hydroxide (2M, 200 ml) and dichloromethane (200 ml) . The organic phase was separated, dried and concentrated to dryness, leaving the crude secondary amine (0.75 g) as viscous oil.
  • TLC silica gel/ethyl acetate
  • the imine (110 g) produced according to step 4 was dissolved in a mixture of methanol and (500 ml) and tetrahydrofuran (500 ml) and treated with sodium borohydride at room temperature until no starting material remained (TLC: silica gel/ethyl acetate). The mixture was concentrated to dryness and partitioned between aqueous sodium hydroxjde (2M, 400 ml) and dichloromethane (600 ml) . The organic phase was separated, dried and concentrated to dryness, leaving the crude secondary amine (109 g) as viscous oil. The amine was converted into its hydrochloride, which was isolated as a white crystalline powder (59.2 g) . ⁇ n analytical sample was obtained crystallization from methanol, m.p. 220-240°C (dec. ) .
  • step 1 The product was isolated as viscous oil .
  • Picropodophyllin used as a standard, showed an IC ⁇ o of around 5 ⁇ M for the inhibition of phospho-MAPK (Erkl/2) .

Abstract

On a synthétisé des composés ayant la formule (I). On a découvert que ces composés régulent vers le bas ou inhibent l'expression ou la fonction du récepteur IGF-1.
PCT/IB2006/002474 2005-09-09 2006-09-08 Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r WO2007029107A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US11/991,531 US20090099133A1 (en) 2005-09-09 2006-09-08 Isoquinolines Derivatives as Igf-1R Inhibitors
BRPI0616731A BRPI0616731A2 (pt) 2005-09-09 2006-09-08 derivados de isoquinolina como inibidores do igf-1r
AU2006288847A AU2006288847A1 (en) 2005-09-09 2006-09-08 Isoquinolines derivatives as IGF-1R inhibitors
EA200800786A EA200800786A1 (ru) 2005-09-09 2006-09-08 Тетрагидроизохинолиновые и тетрагидробензоазепиновые производные в качестве igf-1r ингибиторов, способ лечения или профилактики заболеваний, при которых благоприятна деактивация igf-1r, изделие для введения производных и хемотерапевтических агентов в комбинации, фармакологический инструмент для разработки и стандартизации тест-систем
EP06795449A EP1940796A1 (fr) 2005-09-09 2006-09-08 Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r
JP2008529711A JP2009507820A (ja) 2005-09-09 2006-09-08 Ｉｇｆ−１ｒ阻害剤としてのイソキノリン誘導体
CA002621820A CA2621820A1 (fr) 2005-09-09 2006-09-08 Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r
NO20081206A NO20081206L (no) 2005-09-09 2008-03-07 Isoquinolines derivatives as IGF -1R inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71517005P 2005-09-09 2005-09-09
IB2005002667 2005-09-09
IBPCT/IB2005/002667 2005-09-09
US60/715,170 2005-09-09

Publications (1)

Publication Number Publication Date
WO2007029107A1 true WO2007029107A1 (fr) 2007-03-15

Family

ID=37460368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002474 WO2007029107A1 (fr) 2005-09-09 2006-09-08 Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r

Country Status (10)

Country Link
US (1) US20090099133A1 (fr)
EP (1) EP1940796A1 (fr)
JP (1) JP2009507820A (fr)
KR (1) KR20080065591A (fr)
AU (1) AU2006288847A1 (fr)
BR (1) BRPI0616731A2 (fr)
CA (1) CA2621820A1 (fr)
EA (1) EA200800786A1 (fr)
NO (1) NO20081206L (fr)
WO (1) WO2007029107A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106556A2 (fr) 2011-02-02 2012-08-09 Amgen Inc. Méthodes et compositions associées à l'inhibition d'igf-1r
WO2013071056A2 (fr) 2011-11-11 2013-05-16 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
WO2014015280A1 (fr) 2012-07-20 2014-01-23 Novartis Pharma Ag Polythérapie à base d'inhibiteurs d'igf1 r et de la pi3k
CN103732592A (zh) * 2011-04-21 2014-04-16 默沙东公司 ***-1受体抑制剂
WO2017129763A1 (fr) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement du cancer de l'estomac à cellules en bague à chaton

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
EP3111224B1 (fr) 2014-02-24 2018-12-26 Ventana Medical Systems, Inc. Amplification du signal d'analogues de quinoneméthides
PT3298021T (pt) * 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
WO2018094275A1 (fr) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
WO2004054996A1 (fr) * 2002-12-18 2004-07-01 Biovitrum Ab Nouveaux derives de 1-phenyl-tetrahydronaphtalene substitues et leur utilisation en tant qu'inhibiteurs du recepteur de l'igf-1
WO2005087743A1 (fr) * 2004-03-12 2005-09-22 Analytecon S.A. Derives de tetrahydroisoquinoleine et de tetrahydrobenzazepine utilises comme inhibiteurs de l'igf-1r

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (fr) * 1999-12-24 2001-07-04 Pfizer Inc. Composés de tétrahydroisoquinoline comme agonistes/antagonistes d'oestrogène
WO2004054996A1 (fr) * 2002-12-18 2004-07-01 Biovitrum Ab Nouveaux derives de 1-phenyl-tetrahydronaphtalene substitues et leur utilisation en tant qu'inhibiteurs du recepteur de l'igf-1
WO2005087743A1 (fr) * 2004-03-12 2005-09-22 Analytecon S.A. Derives de tetrahydroisoquinoleine et de tetrahydrobenzazepine utilises comme inhibiteurs de l'igf-1r

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
3 July 2005, AMBINTER STOCK SCREENING COLLECTION, AMBINTER PARIS, FRANCE *
DATABASE CHEMCATS Chemical Abstract Service, Columbus, Ohio, US; XP002410615 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106556A2 (fr) 2011-02-02 2012-08-09 Amgen Inc. Méthodes et compositions associées à l'inhibition d'igf-1r
CN103732592A (zh) * 2011-04-21 2014-04-16 默沙东公司 ***-1受体抑制剂
WO2013071056A2 (fr) 2011-11-11 2013-05-16 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
US9931402B2 (en) 2011-11-11 2018-04-03 Duke University Compositions for the treatment of solid tumors
WO2014015280A1 (fr) 2012-07-20 2014-01-23 Novartis Pharma Ag Polythérapie à base d'inhibiteurs d'igf1 r et de la pi3k
WO2017129763A1 (fr) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement du cancer de l'estomac à cellules en bague à chaton

Also Published As

Publication number Publication date
EP1940796A1 (fr) 2008-07-09
KR20080065591A (ko) 2008-07-14
NO20081206L (no) 2008-05-29
AU2006288847A1 (en) 2007-03-15
JP2009507820A (ja) 2009-02-26
US20090099133A1 (en) 2009-04-16
EA200800786A1 (ru) 2008-08-29
BRPI0616731A2 (pt) 2016-08-23
CA2621820A1 (fr) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007029107A1 (fr) Derives d'isoquinolines utilises en tant qu'inhibiteurs d'igf-1r
TWI236477B (en) beta-carboline compounds which bind to somatostatin receptors and block sodium channels
TWI527824B (zh) 新穎的磷酸鹽化合物，其製備方法及含有其之醫藥組合物
US8044067B2 (en) Isoquinolines as IGF-1R inhibitors
IL177307A (en) Tetrahydroisoquinoline and Tetrahydrobenzazepine Derivatives R 1 - IGF Inhibitors
CA2990564A1 (fr) Derive d'amide heterocyclique bicyclique
CN114163457A (zh) 嘧啶并五元氮杂环化合物及其用途
EP4177258A1 (fr) Composés d'oxyde d'arylphosphine et leur utilisation
CN101282935A (zh) 作为***-1受体抑制剂的异喹啉衍生物
KR102327054B1 (ko) 퀴놀린 유도체 및 alk와 변이된 alk의 저해제로서의 용도
CN118055933A (zh) 选择性parp1抑制剂及其应用
WO2023138691A1 (fr) Composés hétérocycliques fusionnés utilisés comme modulateurs de la signalisation ras
KR20110025751A (ko) 치료적으로 유용한 치환된 1,7-다이페닐-1,2,3,5,6,7-헥사하이드로피리도[3,2,1-ij]퀴놀린 화합물
KR20070000488A (ko) Ｉｇｆ-1ｒ 억제제로서 테트라히드로이소퀴놀린- 및테트라히드로벤즈아제핀 유도체
MXPA06010410A (es) Derivados de tetrahidroisoquinolina y tetrahidrobenzazepina como inhibidores del receptor factor-1 de crecimiento de tipo in sulinico (igf-1r)
KR20060136458A (ko) Ｉｇｆ-1ｒ 억제제로서 테트라히드로이소퀴놀린- 및테트라히드로벤즈아제핀 유도체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680032919.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006288847

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 189884

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/003298

Country of ref document: MX

Ref document number: 2008529711

Country of ref document: JP

Ref document number: 566525

Country of ref document: NZ

Ref document number: 2621820

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006795449

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087006725

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006288847

Country of ref document: AU

Date of ref document: 20060908

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006288847

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2917/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200800786

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11991531

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006795449

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0616731

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080307